Results 151 to 160 of about 59,330 (297)

Prolonged Vancomycin‐Induced Linear IgA Disease in a Patient With Renal Failure

JEADV Clinical Practice, Volume 4, Issue 2, Page 535-539, June 2025.
ABSTRACT A 64‐year‐old man with pneumococcal septic shock and subsequent renal failure underwent treatments with antibiotics including intravenous vancomycin (VCM). Blistering skin lesions appeared 10 days after the initiation of VCM. When the patient was transferred to us 5 months later, blisters with erythema were still observed on the abdomen and ...
Kaori Takezawa, Reiko Noborio, Yuki Nomura, Takahiro Kiyohara, Mako Mine, Takashi Hashimoto   +5 more
wiley   +1 more source

Cross-reactive immune responses between enteroviruses and islet cell autoantigens [PDF]

, 2002
Ohjaaja Merja Roivainen/MIBO ...
Härkönen, Taina
core  

Oxidative Stress in Antigen Processing and Presentation

MedComm – Oncology, Volume 4, Issue 2, June 2025.
Reactive oxygen species (ROS) play a crucial role in antigen processing and presentation, essential for linking innate and adaptive immunity. While balanced ROS levels promote immune function, excess ROS can disrupt antigen recognition, resulting in immune dysfunction.
Qinxia Chang, Yaying Zhang, Xiaojun Liu, Peng Miao, Wenbing Pu, Shanshan Liu, Jing Zhang, Yuan Tian, Guobo Shen, Na Xie   +9 more
wiley   +1 more source

Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1134-1142, June 2025.
In this systematic review and network meta‐analysis of Janus kinase (JAK) inhibitors for alopecia areata (AA), no evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on Severity of Alopecia Tool (SALT) ≤10 (odds ratio,OR: 0.96, 95% credible interval,CrI: 0.18–7.21) and SALT ≤20 (OR: 1.19, 95% CrI: 0.23–10.67) at Week 24 was found ...
D. Aceituno, C. G. Fawsitt, G. M. Power, E. Law, S. Vaghela, H. Thom   +5 more
wiley   +1 more source

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1152-1162, June 2025.
ALLEGRO‐LT (NCT04006457) is an open‐label, phase 3 study investigating the long‐term safety and efficacy of ritlecitinib in patients with alopecia areata (AA). In this analysis in 449 de novo patients with AA and ≥25% scalp hair loss, ritlecitinib demonstrated clinical efficacy and had an acceptable safety profile through Month 24.
C. Tziotzios, R. Sinclair, A. Lesiak, S. Mehlis, M. Kinoshita‐Ise, A. Tsianakas, X. Luo, E. H. Law, R. Ishowo‐Adejumo, R. Wolk, M. Sadrarhami, A. Lejeune   +11 more
wiley   +1 more source

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page 1163-1173, June 2025.
A post hoc analysis of Severity of Alopecia Tool (SALT) score trajectories in patients with alopecia areata who received ritlecitinib 50 mg once‐daily in ALLEGRO‐2b/3 and rolled over into the ongoing, open‐label, Phase 3 ALLEGRO‐LT study. Long‐term response patterns up to Month 24 and variables associated with treatment response are described. Abstract
B. King, P. Mirmirani, K. Lo Sicco, Y. Ramot, R. Sinclair, L. Asfour, K. Ezzedine, C. Paul, M. Ohyama, R. A. Edwards, G. Bonfanti, U. Kerkmann, D. Wajsbrot, R. Ishowo‐Adejumo, S. H. Zwillich, A. Lejeune   +15 more
wiley   +1 more source

Two rheumatoid arthritis–specific autoantigens correlate microbial immunity with autoimmune responses in joints

Journal of Clinical Investigation, 2017
A. Pianta, S. Arvikar, K. Strle, E. Drouin, Qi Wang, C. Costello, A. Steere   +6 more
semanticscholar   +1 more source

Loss of ADAP1/CentA1 Protects Against Autoimmune Demyelination

The FASEB Journal, Volume 39, Issue 9, 15 May 2025.
ADAP1/CentA1 is an actin‐binding protein highly expressed in neurons. Our study describes a novel immunomodulatory function for ADAP1/CentA1 in the context of autoimmune demyelination. Mice lacking ADAP1/CentA1 were found partially resistant to the multiple sclerosis (MS) model experimental autoimmune encephalomyelitis (EAE) due to an altered ...
Jonathan J. Carver, Wyatt P. Bunner, Rachael R. Denbrock, Changhong Yin, Weihua Huang, Erzsebet M. Szatmari, Alessandro Didonna   +6 more
wiley   +1 more source

Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes

Experimental Dermatology, 2017
J. Fuentes-Duculan, Kathleen M. Bonifacio, J. Hawkes, Norma Kunjravia, I. Cueto, Xuan Li, Juana Gonzalez, S. Garcet, J. Krueger   +8 more
semanticscholar   +1 more source

β‐Cell dysfunction in diabetes: The role of neuroplastin

Journal of Diabetes Investigation, Volume 16, Issue 6, Page 986-988, June 2025.
Moon‐Kyu Lee
wiley   +1 more source